Form 4: Edgewise Therapeutics Executive Alan J. Russell Executes Stock Options and Sells Shares
SEC Form 4 Filing
Alan J. Russell, Chief Scientific Officer of Edgewise Therapeutics, exercised stock options and sold shares of common stock on February 5th and 6th, 2025, according to a recent SEC Form 4 filing.
Summary
- On February 5th and 6th, 2025, Alan J. Russell, the Chief Scientific Officer of Edgewise Therapeutics, exercised stock options to acquire common stock at a price of $0.18 per share.
- He then sold a portion of these shares on the same days at an average price of approximately $30.02 and $30.13, respectively.
- The sales were executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 30, 2024.
- Following these transactions, Russell still beneficially owns 14,863 shares of common stock and holds options to purchase 1,347,565 more shares.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a routine disclosure of insider trading activity under a pre-arranged plan. It doesn't necessarily indicate a positive or negative outlook for the company.
Industry Context
This filing is a routine disclosure of insider trading activity. It's common for executives to exercise stock options and sell shares, especially under pre-arranged trading plans like Rule 10b5-1, to manage personal finances and diversify their holdings.
Stakeholder Impact
- The sale of shares by a high-ranking executive could be perceived negatively by some shareholders, but the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| 06/27/2021 | Date stock options were exercisable |
| 09/30/2024 | Date the Rule 10b5-1 Plan was adopted. |
| 02/05/2025 | Date of first transaction: exercise of options and sale of shares. |
| 02/06/2025 | Date of second transaction: exercise of options and sale of shares. |
| 02/07/2025 | Date of signature on the SEC Form 4. |
| 06/27/2032 | Expiration date of stock options |
Keywords
Edgewise Therapeutics, EWTX, Alan J. Russell, Stock Options, SEC Form 4, Insider Trading, Rule 10b5-1 Plan, Common Stock, Chief Scientific Officer
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.